Labiotech.eu

News and Trends 6 Dec 2017

CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia Target

Researchers from the Wellcome Trust Sanger Institute have reported that a new target for the treatment of leukemia has been found. A new drug target for acute myeloid leukemia (AML) has been identified that could open new avenues for the development of new treatments against the deadly disease. Researchers from the Wellcome Trust Sanger Institute have […]

December 6, 2017 - 3 minutesmins - By Alex Dale

advicenne ipo rare disease children drta

News and Trends 6 Dec 2017

Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children

Update (6/12/2017): Advicenne has raised a total of €27M on Euronext Paris, putting its market cap at €112M. Originally published on 21/11/2017 Advicenne is launching an IPO on Euronext Paris to raise the funds to bring the first treatment for dRTA, a rare disease of the kidneys, to the market. Advicenne, based in Nîmes, France, has officially […]

December 6, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 5 Dec 2017

PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody

ChemomAb kicked off its antibody efforts as a company in 2011, and its $10M Series B has attracted none other than Peter Thiel. Israeli biotech has been attracting quite sizeable funds recently, largely those of UK investment outfit Arix Bioscience. Yesterday it was announced that Peter Theil, co-founder of PayPal and assassin of Gawker, led […]

December 5, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Dec 2017

The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons

Following alarming research about the safety of Sanofi’s dengue vaccine, Dengvaxia, The Philippines has halted its sale, distribution and marketing “to protect the general public.” Before Sanofi Pasteur distributed its dengue vaccine, Dengvaxia, there were some concerns that it would make people sicker. Last year, researchers from top American and British institutions confirmed these suspicions […]

December 5, 2017 - 3 minutesmins - By Evelyn Warner

GeneSight eye gene therapy sight restoration

News and Trends 5 Dec 2017

Update: French Gene Therapy Yields Longer Term Sight Restoration, Eyes Phase III

Update (05/12/2017): GenSight has reported a sustained effect of its treatment GS010, which has now been shown to restore sight in patients for at least 2.5 years after administration. Phase III results for the candidate are expected next year. Originally published 14/06/2017 GenSight has announced Phase I/II data revealing that its gene therapy technology can […]

December 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 5 Dec 2017

Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017

Tis the season for Glühwein, Tannenbäume, and lights in Berlin, and Labiotech is celebrating with its year-end lists of the top things that happened this year. First up, the best biotech companies of 2017! After the doozy of 2016 for biotech and pharma, things could only get better this year — and the European industry […]

December 5, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 4 Dec 2017

Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections

Atox Bio develops immune modulators to save patients with severe infections. An oversubscribed Series F financing will support its lead candidate through a Phase II trial. Atox Bio, which has operations in the US and Israel, develops immune modulators for patients with severe infections. The biotech was established at the Hebrew University of Jerusalem and Yissum. […]

December 4, 2017 - 2 minutesmins - By Alex Dale

hypertension treatment idorsia janssen2 1

News and Trends 4 Dec 2017

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart attacks and strokes. Idorsia was born out of Actelion’s massive $30B (€27.9B) acquisition by Johnson & Johnson, retaining all of the former biotech’s early-stage assets. The company develops small molecules for a broad range of […]

December 4, 2017 - 3 minutesmins - By Alex Dale

News and Trends 4 Dec 2017

Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching

Kiadis Pharma starts Phase III trials with ATIR101, a therapy that could make half-matched donors suitable for bone marrow transplant to treat blood cancer. From its Amsterdam headquarters, Kiadis Pharma is developing a technology that could solve one of the biggest problems of bone marrow transplantation: finding a donor match. Currently, a bone marrow transplant is […]

December 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Dec 2017

Novozymes and Danish Pump Producer Set Sail in Pursuit of Clean Water

As part of the company’s HelloScience initiative, Novozymes will combine its enzyme and microbial technology with Grundfos’ water pumps to provide clean water and better sanitation. Novozymes aims to improve industrial performance without harming our planet. Earlier this year, the company set up HelloScience, an online platform bringing together experts in a number of fields […]

December 4, 2017 - 2 minutesmins - By Alex Dale

Interview 4 Dec 2017

Meet the CEO Leading Italy’s Charge to Become a Major Biotech Player

Riccardo Palmisano is CEO of MolMed, the most important Italian biotech, which focuses on gene and cell therapies. We chatted about the company, which hopes to give the cancer therapies field a boost. You may have come across MolMed before, possibly in our recent piece on the top biotechs in Milan. The company was founded […]

December 4, 2017 - 7 minutesmins - By Alex Dale

More News! 2 Dec 2017

Kunstformen der Natur: 19th Century Biology Art in Exhibition

Kunstformen der Natur, by Ernst Haeckel, is a beautiful series of prints that have influenced scientists and artists alike. A Dutch exhibition shows them like never before. In the fashion of the 19th century, Ernst Haeckel was simultaneously a biologist, philosopher, physician, and artist. A Darwin contemporary, although Haeckel supported Lamarckist and other evolutionary theories that are […]

December 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia Target

Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children

PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody

The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons

Update: French Gene Therapy Yields Longer Term Sight Restoration, Eyes Phase III

Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017

Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching

Novozymes and Danish Pump Producer Set Sail in Pursuit of Clean Water

Meet the CEO Leading Italy’s Charge to Become a Major Biotech Player

Kunstformen der Natur: 19th Century Biology Art in Exhibition

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!